Dr. John Cush RheumNow
3 years ago
Shoulder Arthralgias
Featuring Dr. David Liew (Melbourne, Australia) ( @drdavidliew )
Cancer, checkpoint inhibitors and arthralgias. #PMR
https://t.co/FRpIzfnW76 https://t.co/2S3PP1WA3O
Dr. John Cush RheumNow
3 years ago
342 systemic sclerosis pts, ~32% report reproductive probs:
-early menopause onset (45 vs 48y)
-menopause effected by SSc onset & digital ulcers
-More spont Abs(12 vs 4%), premies (22 vs 6%), low birth Wt (27 vs 5%), C-section (49 vs 19%); NOT Infertility https://t.co/Tjjl9sxtja https://t.co/LKzyGR0mlE
It's exciting to be able to have this conversation because it's only in the past year that we have an approved non-corticosteroid therapy for PMR that's been shown to be effective in a well done clinical trial.
Dr. John Cush RheumNow
3 years ago
Hepatotoxicity related to Anakinra has been reported in pediatric rheumatology patients. LFT elevations have been reported with IL-1 inhibition, even after excluding LFTs from the inflamm Dx, other drugs, MAS, etc. Here are 3 case reports. https://t.co/P4Vv2L3u24 https://t.co/ZYBPcgXNi8
On Oct. 6, 2023, Novartis announced the US Food and Drug Administration (FDA) approved an intravenous (IV) formulation of secukinumab (Cosentyx) for use in treating adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).
Dr. John Cush RheumNow
3 years ago
JAKi Safety and Efficacy in bDMARD-IR Patients with RA
View 5-year long-term extension outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. This poster is sponsored by AbbVie US Medical Affairs.https://t.co/Qr3KJXZJOe https://t.co/Ri1eS0q9Rb
Dr. John Cush RheumNow
3 years ago
Difficult #PMR Management
Featuring Dr. Sebastian Sattui (Pittsburgh, PA) PMR with Difficulty Weaning plus Synovitis. QD Clinics are video vignettes with lessons from the clinic.
https://t.co/dLYxwrmbJg
@sattuiSEMD https://t.co/FDuHWJT7Ra
Dr. John Cush RheumNow
3 years ago
PMR & Popeye's Spinach
Dr. Jack Cush reviews the big #PMR reports from this week along with other journal reports from RheumNow.
https://t.co/7oCQmuSATE https://t.co/5qWfZZzNBn
Dr. John Cush RheumNow
3 years ago
Dr. Iain McInnes, Glasgow and Dr. Gerd Burmester, Berlin, discuss their perspectives on the future management of people with rheumatoid arthritis #RA
https://t.co/BhAKRXuzMY https://t.co/MqVHMieqiz https://t.co/zCvO2FbrZA
Dr. John Cush RheumNow
3 years ago
FDA has approved IV secukinumab (Cosentyx), an IL-17 inhibitor for use in adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/48QLLoMvUk https://t.co/mf4IBVLZD9
In patients with rheumatoid arthritis (RA) treated with infliximab (Remicade), increases in body mass index (BMI) scores over time were not associated with increased disease activity or faster radiographic progression.
In fact, erosions were less severe in those with rising BMI, according to Theresa Burkard, PhD, of Eidgenössische Technische Hochschule Zürich in Switzerland, and colleagues.
